

Table S1 Clinical characteristics of thyroid cancer patients from TCGA

Variables		Patients (N=502)	
		n	%
Age	years (mean, range)	47.34 (15.00-89.00)	/
Overall survival times	days (mean, range)	1209.7 (0-5423.0)	/
Overall survival status	Alive	486	96.81
	Dead	16	3.19
Gender	Female	367	73.11
	Male	135	26.89
Race	White	332	66.13
	Others	79	15.74
	Unknown	91	18.13
Thyroid disorder history	Lymphocytic thyroiditis	47	9.36
	Nodular hyperplasia	68	13.55
	Lymphocytic thyroiditis and nodular hyperplasia	24	4.78
	Normal	280	55.78
	Others	25	4.98
	Unknown	58	11.55
PTC subtype	Classical	356	70.92
	Follicular	101	20.12
	Tall Cell	36	7.17
	Others	9	1.79
Location	Bilateral	86	17.13
	Isthmus	22	4.38
	Left lobe	175	34.86
	Right lobe	213	42.43
	Unknown	6	1.20
Residual tumor	R0	384	76.49
	R1	52	10.36
	R2	4	0.80
	RX	30	5.98
	Unknown	32	6.37
Tumor stage	Stage I	281	55.98
	Stage II	52	10.36
	Stage III	112	22.31
	Stage IV	55	10.96
	Unknown	2	0.40
T stage	T1	143	28.49
	T2	164	32.67
	T3	170	33.86
	T4	23	4.58
	TX	2	0.40
N stage	N0	229	45.62
	N1	223	44.42
	NX	50	9.96
M stage	M0	282	56.18
	M1	9	1.79
	MX	210	41.83
	Unknown	1	0.20

TCGA, The Cancer Genome Atlas.

Table S2 The correlation between CRNDE and genes in the WNT signaling pathway

LncRNA	mRNA	P value	Cor	Slope
CRNDE	FZD2	1.17E-11	0.30	0.23
CRNDE	FOSL1	1.29E-09	0.27	0.35
CRNDE	TCF7L1	1.32E-08	0.25	0.28
CRNDE	NFATC1	1.71E-08	0.25	0.16
CRNDE	CSNK1E	2.93E-07	0.23	0.09
CRNDE	WNT2B	6.76E-07	0.22	0.09
CRNDE	WNT5B	2.07E-06	0.21	0.18
CRNDE	VANGL1	2.44E-06	0.21	0.12
CRNDE	PPP2R5B	3.36E-06	0.21	0.08
CRNDE	FZD10	1.27E-05	0.19	0.12
CRNDE	PRICKLE2	1.28E-05	0.19	0.12
CRNDE	RAC3	2.15E-05	0.19	0.14
CRNDE	SOX17	7.09E-05	0.18	0.13
CRNDE	LEF1	1.12E-04	0.17	0.16
CRNDE	PLCB3	1.22E-04	0.17	0.05
CRNDE	PPP2R1B	1.22E-04	0.17	0.06
CRNDE	ROCK2	1.29E-04	0.17	0.08
CRNDE	PLCB1	1.98E-04	0.17	0.09
CRNDE	FZD7	3.19E-04	0.16	0.12
CRNDE	WIF1	3.23E-04	0.16	0.16
CRNDE	SMAD3	5.49E-04	0.15	0.08
CRNDE	WNT9A	1.28E-03	0.14	0.09
CRNDE	RUVBL1	1.38E-03	0.14	0.03
CRNDE	WNT7B	1.98E-03	0.14	0.11
CRNDE	TP53	1.99E-03	0.14	0.05
CRNDE	PRICKLE1	2.27E-03	0.14	0.14
CRNDE	RBX1	2.95E-03	0.13	0.05
CRNDE	NKD1	3.22E-03	0.13	0.06
CRNDE	WNT11	4.26E-03	0.13	0.14
CRNDE	TCF7L2	4.28E-03	0.13	0.06
CRNDE	RAC1	4.98E-03	0.13	0.02
CRNDE	CCND1	5.17E-03	0.12	0.09
CRNDE	SFRP5	5.75E-03	0.12	0.06
CRNDE	SFRP4	6.17E-03	0.12	0.25
CRNDE	JUN	6.79E-03	0.12	0.13
CRNDE	PLCB4	6.97E-03	0.12	0.13
CRNDE	WNT4	9.78E-03	0.12	0.16
CRNDE	PORCN	1.15E-02	0.11	0.07
CRNDE	WNT3A	1.25E-02	0.11	0.06
CRNDE	DKK2	1.31E-02	0.11	0.09
CRNDE	WNT6	1.51E-02	0.11	0.05
CRNDE	FRAT1	1.60E-02	0.11	0.04
CRNDE	SFRP2	1.91E-02	0.10	0.30
CRNDE	FZD6	2.15E-02	0.10	0.07
CRNDE	FZD8	2.26E-02	0.10	0.08
CRNDE	WNT16	3.00E-02	0.10	0.04
CRNDE	FZD4	3.86E-02	0.09	0.06

CRNDE, colorectal neoplasia differentially expressed; LncRNA, long-noncoding RNA; WNT, wnt signaling pathway.